

23

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
29 August 2002 (29.08.2002)

PCT

(10) International Publication Number  
WO 02/066005 A1

(51) International Patent Classification<sup>7</sup>: A61K 9/00, 9/16

(21) International Application Number: PCT/US02/04269

(22) International Filing Date: 14 February 2002 (14.02.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/784,153 16 February 2001 (16.02.2001) US

(71) Applicants (for all designated States except US): CAM-  
BRIDGE BIOSTABILITY LTD [GB/GB]; 52 Bishop's  
Court, Bishop's Road, Cambridge, Cambridgeshire CB2  
NN (GB). IDEA, INC. [US/US]; 400 Seventh Street, NW,  
Washington, DC 20004 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): ROSER, Bruce  
[GB/GB]; 4 Archway Court, Barton Road, Cambridge,  
Cambridgeshire CB3 9LW (GB).

(74) Agents: HOLMAN, John, Clarke, et al.; JACOBSON  
HOLMAN, PLLC, The Jenifer Building, 400 Seventh  
Street, N.W., Washington, DC 20004 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: COMPOSITION AND METHOD FOR CONTROLLED RELEASE INJECTIONS



WO 02/066005 A1

(57) Abstract: The present invention is a pharmaceutical composition and method for controlling the release of a drug or vaccine to a patient where a slow, controlled release of drug or antigen occurs over a considerable period of time after injection. The drug or vaccine is contained in sugar glass microspheres and then placed in an anhydrous liquid, preferably perfluorocarbon, so that the vaccine is protected against dissolution while remaining surrounded by anhydrous liquid. This simple non-toxic system, deliverable by current syringe or present or future needle-free systems, is inexpensive and reliable and aids in parenteral drug delivery or mass immunization campaigns by reducing the need for repeated injections.



- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**COMPOSITION AND METHOD FOR  
CONTROLLED RELEASE INJECTIONS**

**1. Field of the Invention**

This invention relates generally to methods for controlled release of injected drugs and more specifically to controlled release vaccinations, which extend the duration of action of injected drugs or the duration of triggering of the immune response long after injection by slowly releasing the drug or vaccine into the circulatory system.

**2. Background of the Invention**

Currently, vaccinations include the need for multiple injections over time in order to generate a protective memory immune response. Because the immune system responds only modestly to initial contact with antigens, repeat injections are necessary. Immunity is an adaptive or learned process in which each subsequent exposure to antigen elicits a stronger antibody response. The response is stronger, not only in the quantity of antibody made but also in the average affinity (the strength of attachment or binding of the antibody for the antigen.) Affinity increases because only those B cells which possess high-affinity receptors are selectively triggered to proliferation and survival in the later stages of the immune response as the concentration of antigen falls. Early after injection, of course, the concentration of antigen is high enough to trigger both high and low affinity receptors. With repeated antigen injections, a greater number of the specific antibody forming B lymphocytes are produced by this enhanced proliferation and survival as "memory" cells and the quantity of antibody therefore increases.

Typically, a childhood vaccination protocol for diphtheria, tetanus and pertussis (DTP) requires a priming dose of vaccine at 2 months of age, a first booster injection at 4 months of age, a second booster at 6 months of age another dose at 15-18 months, and a recommended final dose at 4-6 years of age (Centers for Disease Control and Prevention, National Immunization Program.) Other vaccines require similar protocols. These vaccine injections cause pain and distress, especially in infants; therefore, child-care providers often fail to return with the children for later injections. As a result, the immunization protocol is compromised and children are not properly protected against disease. The World Health Organization (WHO) identified this failure of compliance as a widespread occurrence resulting in jeopardising mass immunization campaigns. (Jodar L., Aguado T., Lloyd J. and Lambert P-H (1998) Revolutionizing Immunizations Gen. Eng. News 18 p. 6.)

In order to address this problem, considerable efforts have been made to develop techniques which reduce the number of injections required. One approach is controlled release vaccines, which extend the duration of triggering the immune response long after each injection, by slowly releasing the vaccine into the circulation. Most of the work to date addresses the tetanus vaccine encapsulated in bio-erodible plastic microspheres of poly. lactide/glycolide polymers [(Xing D.K.L., McLellan K., Corbel M.J., and Sesardic D. (1996) Estimation of antigenic tetanus toxoid extracted from biodegradable microspheres. *Biologicals* 24, 57-65.] The biodegradable plastics slowly solubilize in body fluids thereby releasing vaccine gradually from the eroded hydrophobic particles after injection. However, the vaccines were found to be unstable in

the body, therefore, early results were disappointing, but newer formulations overcame these problems and tetanus vaccine now works reasonably well in this system. Other fragile vaccines, however, are not stable in plastic particles in the body at 37°C. It is for this reason that no other controlled release vaccine is currently in use.

In the course of developing stable liquids for injection, [(U.S. Patent Appln. No. 09/271,204 Composition and method for stable injectable liquids] stabilized formulations of tetanus vaccine in soluble, sugar glass microspheres suspended in anhydrous oils or perfluorocarbon liquids were studied. The stabilizing agent used was a soluble glass of the sugar alcohol mannitol which, upon contact with body water, it was expected to dissolve immediately and release its vaccine as a conventional priming dose. In pre-clinical testing, the stable liquid formulations were injected subcutaneously into groups of 10 guinea pigs. Dried vaccine was tested soon after manufacture (Figure 1) and after it had been tested for stability by 3 months of accelerated aging at 37°C (Figure 2).

Aliquots of dry vaccine, stabilized in sugar glass, were dissolved in water before injection and served as controls as well as fresh source vaccine as the standard biological control vaccine preparation. Antibody responses were measured at 4, 8, and 12 weeks after injection.

It was found that all the control vaccines produced the typical kinetic response of antibody titer after a priming dose, specifically, the antibody levels peaked at 4-8 weeks and then fell by 12 weeks. However, when both groups were injected with stabilized vaccine in glass microspheres suspended in anhydrous biocompatible liquids, the antibody levels in these animals

continued to rise throughout the whole of the 12 weeks after injection. This result, not seen before in guinea pig tetanus toxoid immunization indicated a distinct change in the kinetics of antibody production. When compared with the historical results of antibody kinetics studies in guinea pigs injected with repeated doses of standard vaccine, the present studies indicated controlled release of antigen. The rising antibody levels seen in the present study at 12 weeks indicated protection of the animals equivalent to that seen after a multiple injection course of standard soluble vaccine.

While sugar glasses have proven to be efficacious in providing a stable milieu for fragile biological molecules, other water-soluble glasses such as the metal carboxylates and similar glasses (Slow Release Vitreous Systems PCT No WO 90/11756) and the phosphate glasses (Phosphate Glass Ceramics for Biological na Medical Applications US patent No 4,698,318) can also be formulated as glass microspheres, either in combination with sugar glasses or separately (Amorphous glasses for stabilizing sensitive products. PCT application WO 99/47174) and have other desirable properties which suit them for use in this system. This includes the ability to pre-determine the rate at which the glass dissolves by formulating it from a mixture of salts with individually different solubility rates in water (Controlled Delivery Devices US patent No 5,270,048).

The stable liquid formulations in anhydrous biocompatible liquids were initially developed to solve two major problems, namely the need to refrigerate drugs or vaccines for storage and the need to reconstitute them in the field with sterile water before injection. Not only does the technology clearly overcome these drawbacks, it appears that these formulations in anhydrous

liquids also solve the compliance problem. A convenient, ready-to-inject, stable vaccine provides a complete course of immunization with a single injection in the present invention.

It is hypothesized that some of the soluble glass microspheres containing the stabilized vaccine are protected against dissolution in body water by remaining surrounded by anhydrous liquid. They dissolve only at some time after injection to release their vaccine, which then acts as a booster dose giving rising levels of antibody throughout the whole 12 weeks of the experiment.

A lower average antibody level at 4 weeks exists with anhydrous liquid preparations than with soluble antigen. This lower early titer in the groups given anhydrous liquid suspensions of vaccine is arguably the result of a lower dose of antigen being released soon after injection. Some may argue this indicates a problem of delayed onset of immunity, however the protective level of antibody in this system is approximately 0.1 international units per milliliter of blood. The levels seen in the guinea pigs at 4 weeks were more than 1 international unit per milliliter, well above the protective level even at such an early stage.

#### **BRIEF SUMMARY OF THE INVENTION**

The present invention is a composition and method for controlled-release injections using soluble glass microspheres suspended in anhydrous liquids such as oils, silicone fluids or perfluorocarbons where a slow, controlled dissolution of the microspheres and release of antigen occurs over a considerable period of time after injection.

For a better understanding of the present invention, together with other and further objects thereof, reference is

made to the following description, taken in conjunction with the accompanying drawings, and its scope will be pointed out in the appending claims.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a view of mean antibody titers of groups of 10 Guinea pigs injected on day 0 with 0.5 ml vaccine and bled at 4, 8 and 12 weeks later.

FIG. 2 is a representation of mean antibody titers of groups of 10 Guinea pigs injected on day 0 with 0.5 ml vaccine and bled at 4, 8 and 12 weeks later.

#### DETAILED DESCRIPTION OF THE INVENTION

In the embodiment labeled Figure 1, groups of 10 Guinea pigs were injected on day 0 with 0.5ml vaccine and bled at 4, 8 and 12 weeks later. In the first panel, animals were injected with fresh liquid vaccine from the manufacturer (Medeva batch T022). The mean antibody titre in animals given fresh vaccine was higher than in the groups given dried vaccine, which suggests some loss of immunogenicity due to the drying protocol. Another 10 animals were injected with vaccine dried into a powder of sugar glass microspheres and rehydrated with water immediately before injection as indicated in the second panel. The third panel illustrates animals injected with vaccine dried into a powder of sugar glass microspheres suspended in 0.5ml squalane oil. The fourth panel illustrates animals injected with vaccine dried into a powder of sugar glass microspheres suspended in 0.5ml perfluorodecalin. Finally, in the fifth panel, animals were injected with a powder of sugar glass microspheres not containing vaccine suspended in 0.5ml of squalane and in the sixth panel animals were injected with a powder of sugar glass microspheres not containing vaccine suspended in 0.5ml of perfluorodecalin.

While the antibody titre in the first two groups of animals injected with aqueous vaccines fell at 12 weeks after injection, the titre in the groups injected with vaccine in oil or PFC did not fall at 12 weeks. There was no antibody response in the fifth and sixth groups of animals injected with the vehicle formulation only.

Figure 2 illustrates an embodiment where mean antibody titers of groups of 10 Guinea pigs were measured after they had been injected on day 0 with 0.5ml vaccine and bled at 4, 8 and 12 weeks later. In the first panel, animals were injected with fresh liquid vaccine from the manufacturer which had been stored at 4°C for 3 months. Another group of animals were injected with fresh liquid vaccine from the manufacturer which had been stored at 37°C for 3 months, as indicated in the second panel. The third panel represents animals injected with vaccine dried into a powder of sugar glass microspheres, stored at 37°C for 3 months and rehydrated with water immediately before injection. The fourth panel illustrates animals injected with vaccine dried into a powder of sugar glass microspheres and suspended in 0.5ml squalane and stored in squalane at 37°C for 3 months before injection. Finally, the fifth panel illustrates animals injected with vaccine dried into a powder of sugar glass microspheres and suspended in 0.5ml perfluorodecalin and stored in PFC at 37°C for 3 months before injection. In this particular embodiment, the antibody titer in animals given fresh vaccine was higher than in the groups given dried vaccine showing some loss of immunogenicity due to the drying protocol. While the antibody titer in the two groups of animals injected with aqueous vaccines which had been stored either wet or dry at 37°C fell at 8 and 12 weeks after injection, the titer in the two groups injected with

vaccine in oil or PFC rose progressively throughout the 12 weeks.

Experiments in vitro had suggested that PFCs might provide immediate release from glass microspheres suspended in them. They involved incorporating a water-soluble dye (Mordant Blue 9) in the sugar glass microspheres, and suspending them at 10% w/v in perfluorodecalin. When 0.5 ml of this opaque dark blue suspension was added to 1.5 ml of water, the PFC suspension fell to the bottom of the tube with the clear water layer on top. After vigorous vortex mixing for approximately one minute and standing for an additional minute, the overlaying water layer became intensely clear blue and the PFC layer cleared to water-white. The clearing of the opacity showed that the suspended particles in the PFC liquid had dissolved. The migration of the blue coloration from the PFC to the water layer showed that all of the hydrophilic dye had dissolved in the water as expected.

#### EXAMPLE 1

Using an easily assayed protein as a model vaccine confirms the above results. The enzyme alkaline phosphatase was chosen. The following solution was made:

Adjuvant grade calcium phosphate 10% w/v (Superphos Kemi a/s); Trehalose, 10% w/v; ZnCl<sub>2</sub>, 1mM; MgCl<sub>2</sub>, 1mM; Alkaline phosphatase, 20U/ml in 5mM Tris HCl buffer, pH 7.6.

The suspension was well mixed for 10 minutes at 37°C to allow the insoluble calcium phosphate to adsorb the soluble alkaline phosphatase. This absorption was measured by centrifuging small aliquots of the suspension to deposit the calcium phosphate out of the suspension, sampling the supernatant solution and

measuring its enzyme kinetics using p-nitrophenyl phosphate as substrate and a wavelength of 405 nm. The remaining suspension was then spray-dried to produce a fine powder. Any desorption of the enzyme after rehydration of the powder was measured in the supernatant as above. The powder was suspended at 20% w/v in perfluorophenanthrene and found to produce a stable suspension.

Table 1.

Sample Tested	Absorbance/min (405 nm)	%
Original solution (25 ul)	0.409	100
Supernatant (25ul) from above	0.034	8
Rehydrated powder (25ul of a 20% w/v in water)	0.425	104
Supernatant from above (25ul)	0.004	1
20% w/v powder in PFC (25 ul)	0.430	105

Thus 92% of the enzyme was adsorbed to the calcium phosphate adjuvant (Table 1). All of this enzyme was eventually recovered for an assay of enzyme activity after being suspended in PFCs in trehalose glass microspheres. These were re-dissolved in water as in the blue dye example above.

This experiment suggested that glass microspheres suspended in PFCs dissolved rapidly when mixed with water *in vitro*, indicating that these preparations would also release their antigen rapidly *in vivo*. This is apparently not the case. Surprisingly, there seems to be a slow, controlled release of antigen over a considerable period of time after injection. The release of antigen in this system is similar to that thought to occur with certain oil-based adjuvant liquid emulsions used in animals, such as Freund's Complete Adjuvant. It is thought that

the slow leaking of the antigen from the droplets of antigen solution dispersed in the mineral oil deposit of Freund's adjuvant is responsible for the greatly augmented immune responses found in animals immunized in this way. [(Freund J. Some aspects of active immunization. *Ann. Rev. Microbiol* 1 291 (1947).] Similar results have been found after immunization with antigens stabilized in sugar glass microspheres suspended in anhydrous biocompatible liquids. A major difference between Freund's adjuvant and the present system is that the former is a liquid emulsion of aqueous antigen solution droplets in oil and therefore inherently unstable while the latter is a stabilized dry solid in a glass microsphere suspension and therefore inherently stable. In addition, Freund's adjuvant is a violent irritant and unacceptable for use in humans [(Immunological adjuvants report of a WHO scientific group meeting held in Geneva from 6 to 10 October 1975) 1976] while the PFC formulation used herein is non-toxic. It causes neither immediate nor delayed irritation or inflammation after injection. It is therefore ideally suited to the development of a single-dose vaccine for use in humans, especially in children, where its lack of irritation is an additional bonus. The ability of these formulations to control the release of actives stabilized in soluble glass microspheres is not of course restricted to vaccines. A wide variety of other drugs require repeated injections for their therapeutic efficacy. Indeed it is exceptional for a parenteral drug to be effective in a single dose. In each case the rate of release of the active molecule from solid solution in the soluble glass into free solution in the body fluids would need to be accurately controlled and would be different for each different active molecule.

While various anhydrous biocompatible liquids can be used in this system, PFCs are preferred because of their great chemical and physical stability, their lack of toxicity, their low viscosity and surface tension and their high density.

TABLE 2. Physicochemical properties of some perfluorocarbons.

PFC	MW	Density (Kg/L)	Viscosity (mPas)	Surface Tension (mN/m)	Vapor Pressure (mbar)
-hexane	338	1.68	0.66	11.10	294
-n-octane	438	1.75	.127	16.98	52
-decalin	462	1.92	5.10	17.60	8.8
-phenanthrene	624	2.03	28.40	19.00	<1

A wide variety of PFC liquids can be obtained depending on the particular parent hydrocarbon molecule that is fluorinated. It is likely that the rate of absorption from the tissues into the bloodstream, and of removal from the body in the exhaled breath is a function of the vapor pressure of the PFC at body temperature. This is in turn generally proportional to molecular weight (Table 2). By carefully choosing a particular PFC, it is likely that the rate of controlled release can be varied over a substantial range. Since the PFC liquids can also be blended together, the release rates can be precisely fixed by choosing an appropriate mixture of PFC liquids.

Calcium phosphate, used as a density matching agent, is insoluble in water and forms a fine, highly-hydrated colloidal suspension which is able to reversibly bind large amounts of macromolecules, especially proteins, from solution. A significant proportion of the antigen present in the tetanus toxoid vaccine used in these studies was bound to both the aluminum hydroxide

adjuvant originally used in the vaccine and to the calcium phosphate suspension used as a density matching substance. The protein antigens bound to these inorganic colloids act as a reservoir for the sustained release seen in the animal studies. The degree of delay in the release profile seems to be much greater when the vaccine is in suspension in PFC liquids than with the aqueous suspension, used as a control. This suggests that the non-aqueous PFC liquid is the critical component in controlling the rate of release from the inorganic colloids. It will require further experimentation to establish whether equally sustained release from PFC liquids can occur if the protein is free in solid solution in the glass microspheres rather than bound to an inorganic colloid.

The use of calcium phosphate in these formulations has additional advantages over and above the matching of the density of the sugar glass microspheres with the PFC liquids. Since the inorganic fraction of bone itself consists of calcium phosphate in the form of hydroxyapatite, the chemistry of this additive is biocompatible and non-toxic. It is safe to assume that calcium phosphate injected in this way will be locally non-toxic and will be slowly solubilized from the injection site and/or the regional draining lymph nodes eventually, leaving no excess.

Before this occurs, the deposit of calcium phosphate at the injection site acts as a positive marker of immunization, which is detectable by medical imaging techniques, such as x-rays or MRI, or even possibly by ultrasound or magnetometry. The ability to positively identify patients who have been immunized is sometimes of real importance in disease eradication programs where local record keeping is imperfect and patients' knowledge of their own immunization history may be incomplete. By substituting other density-regulating materials such as barium

sulphate, titanium dioxide and other insoluble and dense inorganic precipitates or defined mixtures of them, it may be possible to uniquely mark different vaccines with separate density matching chemicals. Then an accurate immunization history may be detectable by relatively superficial medical imaging or detection methods.

While there has been described what are believed to be the preferred embodiments of the present invention, those skilled in the art will recognize that other and further changes and modifications may be made thereto without departing from the spirit of the invention, and it is intended to claim all such changes and modifications as fall within the true scope of the invention.

**WHAT IS CLAIMED IS:**

1. A pharmaceutical composition comprising a stabilized drug or vaccine to be injected into a patient wherein,  
said drug or vaccine is in soluble glass microspheres and  
said soluble glass microspheres are suspended in a biocompatible anhydrous liquid whereby said drug or vaccine is protected against dissolution while remaining surrounded by anhydrous liquid thereby,  
extending the duration of action of the drug or the triggering of the immune response by the vaccine, long after injection by slowly releasing the drug or vaccine into the patient's circulatory system.
2. The pharmaceutical composition according to claim 1 wherein said drug is selected from a group consisting of hormones, analgesics, narcotics, narcotic antagonists, chemotherapeutics, immunosuppressants, growth and differentiation regulators and factors, immunomodulators, contraceptives, vasoactive agents, coagulation modifiers, cardioactives, anti inflammatories and CNS drugs.
3. The pharmaceutical composition according to claim 1 wherein said vaccine is selected from a group consisting of toxins, toxoids, live or killed bacteria, live or killed viruses, live or killed protozoa, recombinant proteins, DNA, RNA, polysaccharides, lipoproteins and lipids and recombinant or synthetic peptides.
4. The pharmaceutical composition according to claim 1 wherein said soluble glass microspheres are selected from a group

consisting of non-reducing sugars and sugar alcohols, metal carboxylates and phosphate glasses.

5. The pharmaceutical composition according to claim 4 wherein said non-reducing sugars are selected from the group consisting of sucrose, trehalose, raffinose, and stachyose.

6. The pharmaceutical composition according to claim 4 wherein said sugar alcohols are selected from the group consisting of mannitol, arabinitol, inositol, glucitol, galactitol, xylitol, maltitol, lactitol, glucopyranosyl sorbitol and glucopyranosyl mannitol.

7. The pharmaceutical composition according to claim 1 wherein said anhydrous biocompatible liquid is selected from a group consisting of anhydrous hydrophilic liquids, anhydrous hydrophobic liquids, anhydrous silicone fluids or anhydrous perfluorocarbons.

8. The pharmaceutical composition according to claim 1 wherein said glass microspheres contain an amount of an insoluble biocompatible high-density agent sufficient to raise the average density of the microspheres to match that of the anhydrous biocompatible liquid in which they are suspended.

9. The pharmaceutical composition according to claim 8 wherein said insoluble biocompatible high-density agent is selected from the group consisting of calcium phosphate, aluminum phosphate, aluminum hydroxide, barium sulphate and titanium dioxide.

10. The pharmaceutical composition according to claim 1, wherein said vaccine is tetanus toxoid.

11. The pharmaceutical composition according to claim 10, wherein said vaccine is adsorbed to an adjuvant.

12. The pharmaceutical composition according to claim 11, wherein said adjuvant is selected from a group consisting of aluminum hydroxide, aluminum phosphate or calcium phosphate.

13. The pharmaceutical composition according to claim 10, wherein a solution of calcium phosphate, trehalose, zinc chloride, magnesium chloride, and Tris buffer is added to aid in the formation of said stabilized tetanus toxoid in said glass microspheres.

14. The pharmaceutical composition according to claim 13, wherein said solution is spray-dried to a fine-powder.

15. The pharmaceutical composition according to claim 14, wherein said powder is suspended in perfluorocarbon to produce a stable suspension.

16. The pharmaceutical composition according to claim 15, wherein said perfluorocarbon is selected from a group consisting of perfluorohexane, perfluorodecalin, perfluorooctane and perfluorophenanthrene.

17. A method of formulating a drug or vaccine to prolong the duration of action when administered in an effective amount, which drug or vaccine is formulated by:

incorporating said drug or vaccine in soluble glass microspheres and


suspending said soluble glass microspheres in a biocompatible anhydrous liquid whereby said drug or vaccine is protected against dissolution while remaining surrounded by anhydrous liquid thereby slowly releasing the drug or vaccine into the patient's circulatory system.

18. The method of claim 17 including the step of producing the soluble glass microspheres is selected from the group consisting of spray-drying, air drying, vacuum drying, emulsion solidification, precipitation or melting and grinding to a fine powder.

19. The method of claim 18 wherein said fine powder is suspended in the anhydrous biocompatible liquid which is a perfluorocarbon.


20. The method of claim 19 wherein said perfluorocarbon is selected from the group consisting of perfluorohexane, perfluorodecalin, perfluoroctane and perfluorophenanthrene.

FIG. 1



2/2

FIG. 2



## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 02/04269A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K9/00 A61K9/16

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, CHEM ABS Data, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 41118 A (EASTBRIDGE) 24 September 1998 (1998-09-24) claims 1,3,5,10 examples 1,2	1-7,17, 18
P,X	US 6 190 701 B1 (BRUCE JOSEPH ROSER; ET AL.) 20 February 2001 (2001-02-20) the whole document	1-20
P,X	WO 01 37804 A (UNIVERSAL PRESERVATION TECHNOLOGIES) 31 May 2001 (2001-05-31) the whole document	1-7, 17-20

 Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

11 July 2002

Date of mailing of the international search report

22/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax. (+31-70) 340-3016

Authorized officer

Ventura Amat, A

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No  
PCT/US 02/04269

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9841118	A 24-09-1998	US	6093468 A	25-07-2000
		AU	6758698 A	12-10-1998
		BR	9808230 A	16-05-2000
		CN	1250354 T	12-04-2000
		EP	1024716 A1	09-08-2000
		HU	0001472 A2	28-08-2000
		JP	2001515548 T	18-09-2001
		NO	994264 A	12-11-1999
		WO	9841118 A1	24-09-1998
US 6190701	B1 20-02-2001	NONE		
WO 0137804	A 31-05-2001	AU	2046101 A	04-06-2001
		WO	0137804 A2	31-05-2001